文献速递头颈甲状腺与浅表介入USCT

微血流成像评估复发性甲状腺癌射频消融有效性的研究:与能量多普勒超声成像的比较

Effectiveness of microvascular flow imaging for radiofrequency ablation in recurrent thyroid cancer: comparison with power Doppler imaging.
PubMed 文献 · Eur Radiol · 2024-07-23

这项回顾性研究纳入80例复发性甲状腺癌患者的110个复发肿瘤,比较微血流成像(MVFI)与能量多普勒超声(PDUS)在射频消融(RFA)前后评估瘤内血流的能力。MVFI在RFA前后均显示更高的血流分级,读者间一致性为κ=0.743,读者内一致性为κ=0.840。以甲状腺CT协议为参考标准,MVFI识别RFA后存活肿瘤的敏感度为81.5%-88.9%、准确度为84.1%-86.4%,均高于PDUS(敏感度51.9%、准确度63.6%-70.5%),且未牺牲特异度。

要点

  • MVFI在RFA前后显示的血流分级均高于PDUS,提示其检测瘤内血流更敏感。
  • MVFI识别RFA后存活肿瘤的敏感度81.5%-88.9%、准确度84.1%-86.4%,高于PDUS的51.9%和63.6%-70.5%。
  • MVFI读者间一致性为κ=0.743,读者内一致性为κ=0.840。

核心结论

  • 在复发性甲状腺癌中,MVFI评估瘤内血流优于PDUS,且具有良好的读者间和读者内一致性,对评估RFA前血流及准确识别RFA后存活肿瘤具有临床价值。

研究设计与样本

  • 回顾性研究纳入80例患者(年龄57±12岁,54例女性)的110个复发肿瘤,于2021年1月至2023年6月间接受RFA,共分析151组PDUS和MVFI图像(RFA前85组、RFA后66组),以甲状腺CT协议为参考标准评估44个病灶。

关键影像表现/征象

  • MVFI在RFA前显示的血流分级高于PDUS(读者1:3.04±1.15 vs. 1.93±1.07,p<0.001;读者2:3.20±0.96 vs. 2.12±1.07,p<0.001)。
  • MVFI在RFA后显示的血流分级高于PDUS(读者1:2.44±1.28 vs. 1.67±1.06,p<0.001;读者2:2.62±1.23 vs. 1.83±0.99,p<0.001)。

诊断标准与关键数值

  • 采用四点量表评估图像上的血流,PDUS与MVFI间隔2周以评估读者间一致性,反向顺序(MVFI-PDUS)间隔1个月重新判读以评估读者内一致性。
  • MVFI识别RFA后存活肿瘤的敏感度为81.5%-88.9%、准确度为84.1%-86.4%,PDUS的敏感度为51.9%(p<0.01)、准确度为63.6%-70.5%(p<0.04),MVFI未牺牲特异度。
  • 读者间一致性κ=0.743,读者内一致性κ=0.840。

临床应用与阅片要点

  • MVFI可用于评估复发性甲状腺癌RFA前的瘤内血流以及识别RFA后存活肿瘤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare microvascular flow imaging (MVFI) and power Doppler ultrasonography imaging (PDUS) for detecting intratumoral vascularity in recurrent thyroid cancer both before and after radiofrequency ablation (RFA).

METHODS: This retrospective study included 80 patients (age, 57 ± 12 years; 54 women) with 110 recurrent tumors who underwent RFA between January 2021 and June 2023. A total of 151 PDUS and MVFI image sets were analyzed (85 pre-RFA, 66 post-RFA). Two readers assessed vascularity on the images using a four-point scale with a 2-week interval between PDUS and MVFI to estimate inter-reader agreement. Intra-reader agreement was determined by reinterpreting images in reverse order (MVFI-PDUS) after a 1-month gap. Additionally, diagnostic performance for identifying viable tumors after RFA was assessed in 44 lesions using thyroid-protocol CT as a reference standard.

RESULTS: MVFI demonstrated higher vascular grades than PDUS, both before (reader 1: 3.04 ± 1.15 vs. 1.93 ± 1.07, p < 0.001; reader 2: 3.20 ± 0.96 vs. 2.12 ± 1.07, p < 0.001) and after RFA (reader 1: 2.44 ± 1.28 vs. 1.67 ± 1.06, p < 0.001; reader 2: 2.62 ± 1.23 vs. 1.83 ± 0.99, p < 0.001). Inter-reader agreement was substantial (κ = 0.743) and intra-reader agreement was almost perfect (κ = 0.840). MVFI showed higher sensitivity (81.5%-88.9%) and accuracy (84.1%-86.4%) than PDUS (sensitivity: 51.9%, p < 0.01; accuracy: 63.6-70.5%, p < 0.04), without sacrificing specificity.

CONCLUSION: MVFI was superior to PDUS for assessing intratumoral vascularity and showed good inter- and intra-reader agreement, highlighting its clinical value for assessing pre-RFA vascularity and accurately identifying post-RFA viable tumors in recurrent thyroid cancer.

CLINICAL RELEVANCE STATEMENT: Microvascular flow imaging (MVFI) is superior to power-Doppler US for assessing intratumoral vascularity; therefore, MVFI can be a valuable tool for assessing vascularity before radiofrequency ablation (RFA) and for identifying viable tumors after RFA in patients with recurrent thyroid cancer.

KEY POINTS: The value of microvascular flow imaging (MVFI) for evaluating intratumoral vascularity is unexplored. MVFI demonstrated higher vascular grades than power Doppler US before and after ablation. Microvascular flow imaging showed higher sensitivity and accuracy than power Doppler US without sacrificing specificity.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Suh PS, Baek JH, Lee JH, et al. Effectiveness of microvascular flow imaging for radiofrequency ablation in recurrent thyroid cancer: comparison with power Doppler imaging. Eur Radiol. 2024. PMID: 39042304. doi:10.1007/s00330-024-10977-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。